Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X4P 001

Drug Profile

X4P 001

Alternative Names: AMD 11070; AMD-070; X4P 001 RD; X4P-001-IO; X4P001

Latest Information Update: 05 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AnorMED
  • Developer X4 Pharmaceuticals
  • Class Antineoplastics; Antiretrovirals; Benzimidazoles; Diamines; Hydroquinones; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists; Cytotoxic T lymphocyte stimulants; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Immunodeficiency disorders
  • Phase II Renal cell carcinoma
  • Phase I/II Malignant melanoma
  • Phase I Solid tumours
  • Discontinued HIV-1 infections

Most Recent Events

  • 07 Dec 2018 X4 Pharmaceuticals terminates the phase I trial in Volunteers in the US (NCT02680782)
  • 01 Dec 2018 Updated adverse events data from a phase II/III trial in Immunological disorders (WHIM syndrome) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)
  • 27 Nov 2018 X4 Pharmaceuticals plans a global phase III trial for Immunodeficiency disorders (WHIM Syndrome) in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top